ClinicalTrials.gg
Status unknownNCT04882293Updated Mar 2, 2022

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

A Phase 3 interventional study of Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose and Atorvastatin (Lipitor ®) in Dyslipidemia Associated With Type II Diabetes Mellitus, sponsored by Laboratorios Silanes S.A. de C.V.. Status unknown at 1 site in Mexico. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Planned enrollment
33rd of 47
78 · median 165
Started
2022
with 1 other
Phase 3
12 of 47
none open now
Registered
43rd of 47
by date

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 43rd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.

Read the detailed description

To assess the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia. Assessing the magnitude of change in lipid profile numbers. And describing the effect on anthropometric, biochemical and clinical indicators, as well as events and adverse reactions that may occur. In patients diagnosed with type 2 diabetes and dyslipidemia (triglycerides> 150 mg / dl, LDL (Low density lipoprotein) cholesterol> 100 mg / dl) and who require pharmacological treatment for lipid control.

03

Conditions studied

  • Dyslipidemia Associated With Type II Diabetes Mellitus

Keywords

  • Dyslipidemia
  • Type 2 diabetes
  • Hypertriglyceridemia
  • Lipid profile
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • That the subject agrees to participate in the study and gives their in writing.
  • Both genres.
  • Age 18 to 75 years old.
  • Diagnosis of type 2 diabetes mellitus with adequate glycemic control defined by ≤ 7.5% at the time of selection.
  • Diagnosis of dyslipidemia prior to the start of the study (LDL cholesterol> 100 mg / dl and triglycerides> 150 mg / dl).
  • Willing to avoid sexual contact or to use a barrier method of while conducting the study.

Exclusion criteria

Exclusion Criteria:

  • The drug is for medical reasons.
  • Consumption of oral , cyclosporine or strong cytochrome p450 (CYP) 3A4 inhibitors, protease inhibitors, erythromycin and azoles.
  • Patients with Type 1 Diabetes Mellitus.
  • Acute or Severe renal dysfunction (glomerular filtration \<30 ml / min / 1.72 m2).
  • History of chronic liver disease or and / or AST ≥ 2 times the , or GGT ≥3 times the upper limit of normal.
  • Chronic or acute pancreatitis except for acute pancreatitis due to severe hypertriglyceridemia (defined by the presence of triglycerides> 1000 mg / dl and / or milky plasma, in the absence of other etiological factors of pancreatitis).
  • Patients with active gallbladder disease (defined as acute or chronic gallbladder disorders associated with clinical signs or symptoms).
  • Patient with a history or presence of myopathies.
  • Pregnant or lactating women.
  • Known contraindication or to the use of any of the components of the drug.
  • The patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks.
  • At the medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver or mental failure or with scheduled surgical or hospital procedures.
  • Be a patient with a working relationship with the principal investigator or the research center or prisoner.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Group A: Atorvastatin / Fenofibrate in fixed dose

    Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral

    Drug: Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose

  • Active comparator
    Group B: Atorvastatin (Lipitor ®)

    Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral

    Drug: Atorvastatin (Lipitor ®)

Interventions

  • DrugAtorvastatin 20 mg / Fenofibrate 160 mg in fixed dose

    Drug page: Atorvastatin

    1 tablet once a day, 20 mg /160 mg, Orally

    Also known as: ATV / FENO

  • 1 tablet once a day, 20 mg, Orally

    Also known as: ATV (Lipitor ®)

06

What researchers measure

Primary outcomes

  1. Magnitude of change in lipid profile figures.

    To assess the magnitude of change in lipid profile figures (Lp \[a\], LDL, and triglycerides) at 2 and 4 months with respect to their baseline measurement and between treatment groups.

    Time frame: Baseline, 2 and 4 months.

  2. Proportion of subjects achieving triglyceride levels <150 mg /dL.

    Describe the proportion of subjects who achieved triglyceride levels \<150 mg / dL at the end of treatment.

    Time frame: 4 months

  3. Describe the proportion of subjects who reduced levels of LDL cholesterol

    Describe the proportion of subjects who reduced levels of LDL cholesterol, under 30% compare to the baseline value.

    Time frame: Baseline and 4 months.

Secondary outcomes

  1. Impact on anthropometric indicators (Weight)

    Describe changes in weight (kg) measurements from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 Months

  2. Impact on anthropometric indicators body mass index (BMI)

    Describe changes in BMI (kg/m2) from baseline to the end of the study (4 months)

    Time frame: Baseline and 4 months

  3. Impact on anthropometric indicators (Waist circumference)

    Describe changes in waist circumference (cm) from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 months

  4. Impact on liver function with aspartate aminotransferas (AST)

    Describe the changes in AST (mg/dL) concentration, between baseline and the end of the study.

    Time frame: Baseline and 4 months

  5. Impact on liver function with Alanine Aminotransferase (ALT)

    Describe the changes in ALT (mg/dL) concentration, between baseline and the end of the study.

    Time frame: Baseline and 4 months

  6. Impact on Glycosylated hemoglobin (HbA1c)

    Describe the changes in HbA1c percentage from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 months

  7. Impact on glucose levels

    Describe the changes in glucose levels (mg/dL) from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 months

  8. Impact on Blood pressure

    Describe the changes in blood pressure (mm Hg) from baseline to the end of the study (4 months). impact on clinical indicators (Blood pressure, Heart rate, Respiratory rate).

    Time frame: Baseline and 4 months

  9. Impact on heart rate

    Describe the changes in heart rate (beats per minute) from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 months

  10. Impact on respiratory rate

    Describe the changes in respiratory rate (Pulses per minute) from baseline to the end of the study (4 months).

    Time frame: Baseline and 4 months

  11. Events and adverse reactions presented.

    Proportion of events and adverse reactions presented during 4 months of treatment.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
  • Laboratorio Silanes, S.A. de C.V.
    Mexico City, 11000, Mexico
    Recruiting
    • Jorge A Gonzalez, PhD · Contactjogonzalez@silanes.com.mx · +5254883785
    • Yulia Romero-Antonio, B.S. · Contactyromero@silanes.com.mx · 5554883700
    • Alberto J Zamora Muciño-Arroyo, M.D. · Principal investigator
    • Joel Rodríguez Saldaña, M.D. · Principal investigator
    • Francisco G Padilla Padilla, M.D. · Principal investigator
    • Juan A Peraza Zaldicar, M.D. · Principal investigator
    • Luis M Román Pintos, PhD · Principal investigator
08

References and documents

Publications

  • Escobedo-de la Pena J, de Jesus-Perez R, Schargrodsky H, Champagne B. [Prevalence of dyslipidemias in Mexico city and Its relation to other cardiovascular risk factors. Results from the CARMELA study]. Gac Med Mex. 2014 Mar-Apr;150(2):128-36. Spanish. PubMed 24603993 ↗
  • Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. J Cardiovasc Pharmacol Ther. 2014 May;19(3):296-303. doi: 10.1177/1074248413518968. Epub 2014 Feb 10. PubMed 24516261 ↗
  • Lella M, Indira K. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 2013 Jul;4(3):166-70. doi: 10.4103/2231-4040.116778. PubMed 24083205 ↗
  • Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002 Jul;25(7):1198-202. doi: 10.2337/diacare.25.7.1198. PubMed 12087019 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for May 2022, 3 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 3 months is below that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
May 11, 2021
StartActual
Feb 15, 2022
Primary completionEst.
May 2022
CompletionEst.
May 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04882293
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Feb 15, 2022
Primary completion
May 2022 (estimated)
Completion
May 2022 (estimated)
Last update
Mar 2, 2022

Study contacts

Jorge A González, PhD
Contact
jogonzalez@silanes.com.mx
5254883785 ext. 3761
Yulia G Romero-Antonio, B.S.
Contact
yromero@silanes.com.mx
5554883700 ext. 3777
Alberto J Zamora Muciño-Arroyo, M.D
principal investigator · Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-AGS)
Joel Rodríguez Saldaña, M.D
principal investigator · Resultados médicos, desarrollo e investigación SC (REMEDI)
Francisco G Padilla Padilla, M.D
principal investigator · Independent
Juan A Peraza Zaldivar, M.D
principal investigator · Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-GDL)
Luis M Román Pintos, PhD
principal investigator · Hospital Hispano S.A de C.V

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion